PMID- 15930352
OWN - NLM
STAT- MEDLINE
DCOM- 20050829
LR  - 20220330
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 11
IP  - 11
DP  - 2005 Jun 1
TI  - Clinical evaluation of dendritic cell vaccination for patients with recurrent 
      glioma: results of a clinical phase I/II trial.
PG  - 4160-7
AB  - PURPOSE: To investigate the safety and the immunologic and clinical responses of 
      dendritic cell therapy for patients with recurrent malignant glioma. EXPERIMENTAL 
      DESIGN: Twenty-four patients with recurrent malignant glioma (6 grade 3 and 18 
      grade 4 patients) were evaluated in a phase I/II clinical study of dendritic cell 
      therapy. All patients were resistant to the standard maximum therapy. The 
      patient's peripheral blood dendritic cells were generated with granulocyte 
      macrophage colony-stimulating factor, plus interleukin 4 with or without OK-432, 
      and pulsed with an autologous tumor lysate. Dendritic cells were injected 
      intradermally, or both intratumorally and intradermally every 3 weeks. RESULTS: 
      The protocols were well tolerated with only local redness and swelling at the 
      injection site in several cases. Clinical responses were as follows: 1 patient 
      with partial response, 3 patients with minor response, 10 patients with stable 
      disease, and 10 patients with progressive disease. The patients whose dendritic 
      cells were matured with OK-432 had longer survival times than the dendritic cells 
      from patients without OK-432 maturation. The patients with both intratumoral and 
      intradermal administrations had a longer survival time than the patients with 
      intradermal administration only. Increased ELISPOT and delayed-type 
      hypersensitivity responses after vaccination could provide good laboratory 
      markers to predict the clinical outcome of patients receiving dendritic cell 
      vaccination. The overall survival of patients with grade 4 glioma was 480 days, 
      which was significantly better than that in the control group. CONCLUSIONS: This 
      study showed the safety and clinical response of autologous tumor lysate-pulsed 
      dendritic cell therapy for patients with malignant glioma. Dendritic cell therapy 
      is recommended for further clinical studies in malignant glioma patients.
FAU - Yamanaka, Ryuya
AU  - Yamanaka R
AD  - Department of Neurosurgery, Brain Research Institute, Niigata University School 
      of Medicine, Niigata University, Niigata, Japan. ryaman@bri-niigata-u.ac.jp
FAU - Homma, Junpei
AU  - Homma J
FAU - Yajima, Naoki
AU  - Yajima N
FAU - Tsuchiya, Naoto
AU  - Tsuchiya N
FAU - Sano, Masakazu
AU  - Sano M
FAU - Kobayashi, Tsutomu
AU  - Kobayashi T
FAU - Yoshida, Seiichi
AU  - Yoshida S
FAU - Abe, Takashi
AU  - Abe T
FAU - Narita, Miwako
AU  - Narita M
FAU - Takahashi, Masuhiro
AU  - Takahashi M
FAU - Tanaka, Ryuichi
AU  - Tanaka R
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cancer Vaccines/administration & dosage/immunology
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Glioma/mortality/pathology/*therapy
MH  - Humans
MH  - Immunotherapy, Adoptive/methods
MH  - Injections, Intradermal
MH  - Injections, Intralesional
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2005/06/03 09:00
MHDA- 2005/08/30 09:00
CRDT- 2005/06/03 09:00
PHST- 2005/06/03 09:00 [pubmed]
PHST- 2005/08/30 09:00 [medline]
PHST- 2005/06/03 09:00 [entrez]
AID - 11/11/4160 [pii]
AID - 10.1158/1078-0432.CCR-05-0120 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2005 Jun 1;11(11):4160-7. doi: 10.1158/1078-0432.CCR-05-0120.